Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 12, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding shareholding changes within an employee retirement plan and does not contain financial performance data.
Material Changes
The only material change disclosed is a reduction in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Previous Holding: 18,429,785 ADRs
- New Holding: 18,360,149 ADRs
- Change Date: September 8, 2005
- Average Price: $49.45
The change resulted from a movement in the fund. Two directors, Dr. J.P. Garnier and Dr. T. Yamada, are noted as potentially interested in these shares as beneficiaries of the discretionary fund.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific transaction described above.
Investor Verification Checklist
- Verify the impact of the fund movement on the total share count of the GlaxoSmithKline US Retirement Savings Plan.
- Confirm the potential interest of Directors Dr. J.P. Garnier and Dr. T. Yamada in the Plan's holdings.
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.